Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer
- Yajun Guo
- Lijuan Wang
- Peng Lv
- Peng Zhang
Affiliations: Department of Nursing, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Heping, Tianjin 300052, P.R. China
- Published online on: December 30, 2014 https://doi.org/10.3892/ol.2014.2840
Copyright: © Guo
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
In the present study, a targetable vector was developed for the targeted delivery of anticancer agents, consisting of lipid‑coated poly D,L‑lactic‑co‑glycolic acid nanoparticles (PLGA‑NP) that were modified with transferrin (TF). Doxorubicin (DOX) was used as a model drug for lung cancer therapy. The use of these NPs combined the advantages and avoided the disadvantages exhibited individually by liposomes and polymeric NPs during drug delivery. The lipid coating of the polymeric core was confirmed by transmission electron microscopy. The physicochemical characteristics of transferrin‑conjugated lipid‑coated NPs (TF‑LP), including the particle size, zeta potential, morphology, encapsulation efficiency and in vitro DOX release, were also evaluated. The cellular uptake investigation in the present study found that TF‑LP was more efficiently endocytosed by the A549 cells, than LP and PLGA‑NPs. Furthermore, the anti‑proliferative effect exhibited by DOX‑loaded TF‑LPs on A549 cells and the inhibition of tumor spheroid growth was stronger compared with the effect of DOX‑loaded lipid‑coated PLGA‑NPs and PLGA‑NPs. In the in vivo component of the present study, TF‑LP demonstrated the best inhibitory effect on tumor growth in the A549 tumor‑bearing mice. It was concluded that TF‑LP may be an efficient targeted drug‑delivery system for lung cancer therapy.